Get N for Each Cancer

Characteristic N = 21,6021
Cancer type
    Breast 7,459 (35%)
    Colorectal 3,242 (15%)
    Lung/Bronchus 6,066 (28%)
    Prostate 4,835 (22%)
1 n (%)
Treatment by Cancer
Characteristic Overall
N = 21,6021		 Breast
N = 7,4591		 Colorectal
N = 3,2421		 Lung/Bronchus
N = 6,0661		 Prostate
N = 4,8351
Surgery




    Yes 12,671 (59%) 6,935 (93%) 2,634 (81%) 1,590 (26%) 1,512 (31%)
    No 7,669 (36%) 354 (4.7%) 487 (15%) 3,702 (61%) 3,126 (65%)
    Too risky/patient died 915 (4.2%) 69 (0.9%) 51 (1.6%) 676 (11%) 119 (2.5%)
    Recommended, patient refused 269 (1.2%) 65 (0.9%) 46 (1.4%) 89 (1.5%) 69 (1.4%)
    Unknown 78 (0.4%) 36 (0.5%) 24 (0.7%) 9 (0.1%) 9 (0.2%)
Chemotherapy




    Yes 6,086 (28%) 1,958 (26%) 1,391 (43%) 2,628 (43%) 109 (2.3%)
    No 13,896 (64%) 5,049 (68%) 1,490 (46%) 2,697 (44%) 4,660 (96%)
    Too risky/patient died 596 (2.8%) 89 (1.2%) 143 (4.4%) 340 (5.6%) 24 (0.5%)
    Recommended, patient refused 855 (4.0%) 299 (4.0%) 158 (4.9%) 364 (6.0%) 34 (0.7%)
    Unknown 169 (0.8%) 64 (0.9%) 60 (1.9%) 37 (0.6%) 8 (0.2%)
Hormone therapy




    Yes 6,872 (32%) 4,971 (67%) 2 (<0.1%) 20 (0.3%) 1,879 (39%)
    No 13,562 (63%) 1,490 (20%) 3,221 (99%) 6,018 (99%) 2,833 (59%)
    Too risky/patient died 84 (0.4%) 63 (0.8%) 1 (<0.1%) 8 (0.1%) 12 (0.2%)
    Recommended, patient refused 692 (3.2%) 592 (7.9%) 5 (0.2%) 13 (0.2%) 82 (1.7%)
    Unknown 392 (1.8%) 343 (4.6%) 13 (0.4%) 7 (0.1%) 29 (0.6%)
Radiation




    Yes 8,800 (41%) 3,811 (51%) 651 (20%) 2,587 (43%) 1,751 (36%)
    No 11,386 (53%) 2,941 (39%) 2,488 (77%) 3,079 (51%) 2,878 (60%)
    Too risky/patient died 316 (1.5%) 99 (1.3%) 28 (0.9%) 160 (2.6%) 29 (0.6%)
    Recommended, patient refused 816 (3.8%) 475 (6.4%) 35 (1.1%) 197 (3.2%) 109 (2.3%)
    Unknown 284 (1.3%) 133 (1.8%) 40 (1.2%) 43 (0.7%) 68 (1.4%)
Immunotherapy




    Yes 2,366 (11%) 637 (8.5%) 178 (5.5%) 1,518 (25%) 33 (0.7%)
    No 18,877 (87%) 6,748 (90%) 3,022 (93%) 4,315 (71%) 4,792 (99%)
    Too risky/patient died 125 (0.6%) 8 (0.1%) 16 (0.5%) 99 (1.6%) 2 (<0.1%)
    Recommended, patient refused 148 (0.7%) 32 (0.4%) 13 (0.4%) 101 (1.7%) 2 (<0.1%)
    Unknown 86 (0.4%) 34 (0.5%) 13 (0.4%) 33 (0.5%) 6 (0.1%)
1 n (%)

Get N for each cancer after excluding patients for whom treatment was too risky or who died

Table before excluding patients who died/treatment too risky N = 21,6021
Cancer type
    Breast 7,459 (35%)
    Colorectal 3,242 (15%)
    Lung/Bronchus 6,066 (28%)
    Prostate 4,835 (22%)
1 n (%)
Table after excluding patients who died/treatment too risky N = 19,9601
Cancer type
    Breast 7,200 (36%)
    Colorectal 3,057 (15%)
    Lung/Bronchus 5,032 (25%)
    Prostate 4,671 (23%)
1 n (%)
Table 1. Patients with Incident Breast, Colorectal, Lung/Bronchus, and Prostate Cancers, Maine Cancer Registry, 2017-2021 (n=19,960
Characteristic Overall
N = 19,9471		 2017
N = 3,8201		 2018
N = 3,7781		 2019
N = 4,1181		 2020
N = 3,8751		 2021
N = 4,3561
Cancer type





    Breast 7,194 (36%) 1,400 (37%) 1,336 (35%) 1,468 (36%) 1,345 (35%) 1,645 (38%)
    Colorectal 3,054 (15%) 606 (16%) 579 (15%) 641 (16%) 587 (15%) 641 (15%)
    Lung/Bronchus 5,031 (25%) 961 (25%) 971 (26%) 1,033 (25%) 1,061 (27%) 1,005 (23%)
    Prostate 4,668 (23%) 853 (22%) 892 (24%) 976 (24%) 882 (23%) 1,065 (24%)
Age at diagnosis 67 (12) 67 (12) 67 (12) 67 (12) 67 (11) 67 (12)
Age Group (at dx)





    Age <= 49 1,646 (8.3%) 316 (8.3%) 333 (8.8%) 329 (8.0%) 298 (7.7%) 370 (8.5%)
    Age 50-64 6,480 (32%) 1,297 (34%) 1,232 (33%) 1,367 (33%) 1,220 (31%) 1,364 (31%)
    Age 65-74 7,237 (36%) 1,357 (36%) 1,342 (36%) 1,467 (36%) 1,444 (37%) 1,627 (37%)
    Age 75+ 4,584 (23%) 850 (22%) 871 (23%) 955 (23%) 913 (24%) 995 (23%)
Sex





    Female 11,264 (56%) 2,213 (58%) 2,105 (56%) 2,322 (56%) 2,172 (56%) 2,452 (56%)
    Male 8,683 (44%) 1,607 (42%) 1,673 (44%) 1,796 (44%) 1,703 (44%) 1,904 (44%)
White





    White 19,569 (98%) 3,745 (98%) 3,706 (98%) 4,040 (98%) 3,817 (99%) 4,261 (98%)
    Other 310 (1.6%) 67 (1.8%) 60 (1.6%) 71 (1.7%) 41 (1.1%) 71 (1.6%)
    Unknown 68 (0.3%) 8 (0.2%) 12 (0.3%) 7 (0.2%) 17 (0.4%) 24 (0.6%)
Insurance





    Commercial 6,521 (33%) 1,310 (34%) 1,242 (33%) 1,338 (32%) 1,240 (32%) 1,391 (32%)
    Medicare 9,016 (45%) 1,694 (44%) 1,709 (45%) 1,814 (44%) 1,752 (45%) 2,047 (47%)
    Medicaid 1,256 (6.3%) 207 (5.4%) 211 (5.6%) 283 (6.9%) 272 (7.0%) 283 (6.5%)
    Medicare/Medicaid 1,848 (9.3%) 365 (9.6%) 341 (9.0%) 396 (9.6%) 358 (9.2%) 388 (8.9%)
    Veterans/public health service 777 (3.9%) 128 (3.4%) 149 (3.9%) 153 (3.7%) 178 (4.6%) 169 (3.9%)
    Not insured 268 (1.3%) 68 (1.8%) 69 (1.8%) 65 (1.6%) 31 (0.8%) 35 (0.8%)
    Unknown 261 (1.3%) 48 (1.3%) 57 (1.5%) 69 (1.7%) 44 (1.1%) 43 (1.0%)
Rural Classification





    Urban 9,947 (50%) 1,916 (50%) 1,906 (50%) 2,032 (49%) 1,926 (50%) 2,167 (50%)
    Large rural 3,423 (17%) 574 (15%) 584 (15%) 738 (18%) 743 (19%) 784 (18%)
    Small rural 2,511 (13%) 493 (13%) 490 (13%) 533 (13%) 472 (12%) 523 (12%)
    Isolated rural 4,066 (20%) 837 (22%) 798 (21%) 815 (20%) 734 (19%) 882 (20%)
ADI Quintile





    ADI_Q1 3,278 (16%) 599 (16%) 662 (18%) 656 (16%) 616 (16%) 745 (17%)
    ADI_Q2 4,084 (20%) 804 (21%) 759 (20%) 802 (19%) 821 (21%) 898 (21%)
    ADI_Q3 4,262 (21%) 774 (20%) 792 (21%) 960 (23%) 833 (21%) 903 (21%)
    ADI_Q4 4,615 (23%) 902 (24%) 839 (22%) 957 (23%) 906 (23%) 1,011 (23%)
    ADI_Q5 3,375 (17%) 666 (17%) 669 (18%) 685 (17%) 636 (16%) 719 (17%)
    Unknown 333 (1.7%) 75 (2.0%) 57 (1.5%) 58 (1.4%) 63 (1.6%) 80 (1.8%)
Stage





    In situ 1,313 (6.6%) 272 (7.1%) 229 (6.1%) 265 (6.4%) 217 (5.6%) 330 (7.6%)
    Localized 10,454 (52%) 1,946 (51%) 2,014 (53%) 2,098 (51%) 2,027 (52%) 2,369 (54%)
    Regional 4,692 (24%) 933 (24%) 872 (23%) 1,038 (25%) 918 (24%) 931 (21%)
    Distant 3,488 (17%) 669 (18%) 663 (18%) 717 (17%) 713 (18%) 726 (17%)
1 n (%); Median (SD)
Treatment Characteristics of Patients with Breast Cancer in Maine, According to Rurality and ADI
Characteristic
RUCA Measure
ADI
Urban
N = 2,8731		 Large rural
N = 9371		 Small rural
N = 6081		 Isolated rural
N = 1,0671		 p-value2 ADI_Q1
N = 1,0191		 ADI_Q2
N = 1,2751		 ADI_Q3
N = 1,1321		 ADI_Q4
N = 1,1241		 ADI_Q5
N = 8401		 p-value2
Localized or Regional
Surgical Resection 2,793 (100%) 919 (100%) 592 (100%) 1,048 (100%) 0.3 995 (100%) 1,243 (100%) 1,114 (100%) 1,086 (100%) 822 (100%) 0.6
Chemotherapy 483 (17%) 157 (17%) 102 (17%) 144 (14%) 0.087 168 (17%) 232 (18%) 197 (17%) 158 (14%) 113 (14%) 0.017
Radiation 1,408 (50%) 471 (50%) 269 (46%) 487 (46%) 0.12 494 (49%) 648 (51%) 561 (50%) 538 (48%) 348 (43%) 0.005
Hormone therapy 1,873 (68%) 652 (71%) 373 (67%) 700 (69%) 0.3 657 (66%) 842 (68%) 748 (69%) 774 (72%) 508 (66%) 0.021
Immunotherapy 176 (6.1%) 76 (8.1%) 35 (5.9%) 59 (5.5%) 0.087 72 (7.1%) 93 (7.3%) 79 (7.0%) 56 (5.0%) 39 (4.7%) 0.027
Time to treatment (days) 39 (30) 38 (27) 32 (35) 37 (32) <0.001 40 (30) 38 (31) 38 (29) 38 (30) 34 (31) <0.001
Distant (Advanced Stage)
Surgical Resection 689 (100%) 273 (100%) 164 (100%) 272 (100%) 0.5 244 (100%) 311 (100%) 293 (100%) 306 (100%) 219 (100%) 0.6
Chemotherapy 525 (62%) 201 (64%) 110 (55%) 192 (59%) 0.2 185 (64%) 239 (63%) 222 (64%) 202 (54%) 159 (58%) 0.025
Radiation 583 (70%) 215 (71%) 117 (59%) 212 (67%) 0.023 215 (76%) 266 (72%) 242 (71%) 226 (62%) 156 (60%) <0.001
Hormone therapy 614 (75%) 226 (75%) 153 (82%) 244 (79%) 0.2 232 (82%) 277 (76%) 259 (77%) 257 (73%) 191 (77%) 0.12
Immunotherapy 157 (18%) 63 (20%) 17 (8.5%) 43 (13%) <0.001 50 (17%) 75 (20%) 63 (18%) 48 (13%) 38 (14%) 0.075
Time to treatment (days) 29 (37) 32 (29) 33 (34) 31 (36) 0.3 32 (37) 28 (34) 29 (35) 32 (34) 33 (34) 0.3
1 n (%); Median (IQR)
2 Fisher’s exact test; Pearson’s Chi-squared test; Kruskal-Wallis rank sum test
Treatment Characteristics of Patients with Colorectal Cancer in Maine, According to Rurality and ADI
Characteristic
RUCA Measure
ADI
Urban
N = 6341		 Large rural
N = 2221		 Small rural
N = 1821		 Isolated rural
N = 2361		 p-value2 ADI_Q1
N = 1851		 ADI_Q2
N = 2551		 ADI_Q3
N = 2921		 ADI_Q4
N = 3081		 ADI_Q5
N = 2141		 p-value2
Localized or Regional
Surgical Resection 564 (99%) 216 (100%) 164 (99%) 215 (99%) 0.4 165 (99%) 232 (100%) 272 (100%) 283 (99%) 188 (98%) 0.071
Chemotherapy 101 (16%) 27 (12%) 19 (11%) 24 (10%) 0.070 26 (14%) 37 (15%) 42 (14%) 40 (13%) 23 (11%) 0.8
Radiation 83 (13%) 23 (10%) 18 (10%) 27 (11%) 0.6 17 (9.2%) 35 (14%) 41 (14%) 37 (12%) 20 (9.6%) 0.3
Hormone therapy










    No 630 (100%) 222 (100%) 181 (100%) 235 (100%)
185 (100%) 254 (100%) 292 (100%) 306 (100%) 211 (100%)
Immunotherapy 3 (0.5%) 0 (0%) 0 (0%) 0 (0%) 0.7 0 (0%) 2 (0.8%) 0 (0%) 1 (0.3%) 0 (0%) 0.3
Time to treatment (days) 1 (34) 0 (24) 0 (25) 4 (35) 0.016 0 (30) 0 (31) 2 (29) 0 (35) 4 (29) 0.8
Distant (Advanced Stage)
Surgical Resection 638 (100%) 259 (100%) 192 (100%) 265 (100%) 0.9 207 (100%) 263 (100%) 295 (100%) 333 (100%) 234 (100%) 0.9
Chemotherapy 537 (66%) 220 (68%) 169 (71%) 261 (71%) 0.3 164 (63%) 241 (71%) 268 (71%) 292 (68%) 207 (68%) 0.2
Radiation 218 (27%) 106 (32%) 53 (22%) 100 (27%) 0.057 71 (27%) 96 (28%) 112 (29%) 122 (28%) 71 (23%) 0.4
Hormone therapy 2 (0.2%) 0 (0%) 0 (0%) 0 (0%) >0.9 0 (0%) 1 (0.3%) 0 (0%) 1 (0.2%) 0 (0%) 0.9
Immunotherapy 72 (8.7%) 32 (9.8%) 28 (11%) 36 (9.6%) 0.7 25 (9.3%) 27 (7.8%) 35 (9.2%) 47 (11%) 33 (11%) 0.7
Time to treatment (days) 20 (36) 23 (36) 18 (35) 26 (40) 0.042 20 (37) 21 (37) 20 (34) 24 (39) 21 (39) 0.9
1 n (%); Median (IQR)
2 Fisher’s exact test; Pearson’s Chi-squared test; Kruskal-Wallis rank sum test
Treatment Characteristics of Patients with Lung/Bronchus Cancer in Maine, According to Rurality and ADI
Characteristic
RUCA Measure
ADI
Urban
N = 7791		 Large rural
N = 2581		 Small rural
N = 1881		 Isolated rural
N = 2861		 p-value2 ADI_Q1
N = 1941		 ADI_Q2
N = 2561		 ADI_Q3
N = 3381		 ADI_Q4
N = 3891		 ADI_Q5
N = 3071		 p-value2
Localized or Regional
Surgical Resection 445 (100%) 161 (100%) 113 (100%) 180 (99%) 0.8 123 (100%) 159 (100%) 201 (100%) 215 (99%) 187 (100%) 0.3
Chemotherapy 71 (9.1%) 27 (10%) 21 (11%) 17 (6.0%) 0.2 21 (11%) 23 (9.0%) 28 (8.3%) 37 (9.5%) 25 (8.1%) 0.8
Radiation 260 (34%) 72 (28%) 54 (29%) 82 (29%) 0.2 61 (31%) 79 (31%) 106 (32%) 126 (33%) 88 (29%) 0.9
Hormone therapy 1 (0.1%) 1 (0.4%) 0 (0%) 0 (0%) 0.5 1 (0.5%) 0 (0%) 1 (0.3%) 0 (0%) 0 (0%) 0.3
Immunotherapy 16 (2.1%) 6 (2.3%) 9 (4.8%) 6 (2.1%) 0.2 5 (2.6%) 4 (1.6%) 7 (2.1%) 9 (2.3%) 12 (3.9%) 0.5
Time to treatment (days) 48 (59) 32 (56) 48 (66) 42 (59) <0.001 46 (58) 42 (56) 40 (54) 39 (68) 50 (58) 0.2
Distant (Advanced Stage)
Surgical Resection 285 (99%) 113 (98%) 94 (98%) 147 (98%) >0.9 69 (97%) 96 (99%) 149 (99%) 168 (99%) 147 (97%) 0.5
Chemotherapy 1,104 (63%) 363 (65%) 265 (56%) 429 (60%) 0.005 313 (67%) 425 (66%) 487 (63%) 500 (57%) 408 (60%) <0.001
Radiation 792 (46%) 256 (46%) 193 (41%) 268 (37%) <0.001 210 (45%) 289 (45%) 329 (43%) 385 (44%) 282 (42%) 0.8
Hormone therapy 9 (0.5%) 0 (0%) 4 (0.8%) 4 (0.6%) 0.2 1 (0.2%) 3 (0.5%) 3 (0.4%) 4 (0.4%) 6 (0.9%) 0.6
Immunotherapy 693 (40%) 227 (41%) 150 (31%) 245 (34%) <0.001 200 (42%) 295 (46%) 285 (37%) 302 (34%) 219 (32%) <0.001
Time to treatment (days) 24 (38) 25 (36) 22 (43) 27 (43) 0.14 26 (34) 24 (41) 22 (36) 25 (41) 26 (43) 0.062
1 n (%); Median (IQR)
2 Fisher’s exact test; Pearson’s Chi-squared test; Kruskal-Wallis rank sum test
Treatment Characteristics of Patients with Prostate Cancer in Maine, According to Rurality and ADI
Characteristic
RUCA Measure
ADI
Urban
N = 1,6921		 Large rural
N = 6101		 Small rural
N = 4471		 Isolated rural
N = 7481		 p-value2 ADI_Q1
N = 6381		 ADI_Q2
N = 6941		 ADI_Q3
N = 7521		 ADI_Q4
N = 8291		 ADI_Q5
N = 5181		 p-value2
Localized or Regional
Surgical Resection 491 (99%) 174 (98%) 130 (94%) 201 (96%) 0.022 173 (98%) 172 (96%) 219 (96%) 253 (98%) 156 (99%) 0.4
Chemotherapy 3 (0.2%) 2 (0.3%) 0 (0%) 1 (0.1%) 0.8 1 (0.2%) 2 (0.3%) 1 (0.1%) 1 (0.1%) 1 (0.2%) >0.9
Radiation 637 (38%) 232 (38%) 164 (37%) 248 (34%) 0.2 264 (42%) 283 (41%) 270 (36%) 256 (31%) 190 (37%) <0.001
Hormone therapy 476 (28%) 166 (27%) 145 (33%) 206 (28%) 0.2 187 (29%) 197 (29%) 190 (25%) 230 (28%) 171 (33%) 0.048
Immunotherapy 1 (<0.1%) 0 (0%) 0 (0%) 2 (0.3%) 0.3 0 (0%) 0 (0%) 2 (0.3%) 1 (0.1%) 0 (0%) 0.5
Time to treatment (days) 49 (71) 55 (76) 48 (76) 38 (69) <0.001 53 (65) 48 (67) 49 (77) 42 (73) 49 (72) 0.057
Distant (Advanced Stage)
Surgical Resection 215 (100%) 89 (99%) 55 (100%) 118 (100%) 0.3 85 (100%) 95 (100%) 107 (99%) 103 (100%) 72 (100%) >0.9
Chemotherapy 47 (8.9%) 14 (7.1%) 17 (12%) 22 (7.5%) 0.4 18 (8.7%) 16 (6.9%) 15 (6.3%) 29 (11%) 20 (9.7%) 0.3
Radiation 170 (33%) 74 (38%) 43 (30%) 90 (31%) 0.3 64 (32%) 80 (35%) 79 (33%) 81 (32%) 65 (32%) >0.9
Hormone therapy 347 (66%) 125 (64%) 105 (71%) 202 (69%) 0.4 129 (64%) 160 (70%) 156 (65%) 168 (66%) 149 (73%) 0.2
Immunotherapy 9 (1.7%) 9 (4.6%) 6 (4.1%) 4 (1.4%) 0.044 2 (1.0%) 3 (1.3%) 9 (3.8%) 7 (2.7%) 7 (3.4%) 0.2
Time to treatment (days) 43 (74) 44 (54) 33 (55) 47 (80) 0.2 45 (74) 42 (76) 44 (65) 42 (71) 41 (67) 0.9
1 n (%); Median (IQR)
2 Fisher’s exact test; Pearson’s Chi-squared test; Kruskal-Wallis rank sum test